[1. GRAEBER KE, OLSEN NJ. Th17 cell cytokine secretion profile in host defense and autoimmunity. Inflamm Res. 2012; 61 (2):87-96.10.1007/s00011-011-0419-1]Open DOISearch in Google Scholar
[2. HYMOWITZ SG, FILVAROFF EH, YIN JP, LEE J, CAI L, RISSER P, et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J. 2001; 20:5332–41.10.1093/emboj/20.19.5332]Open DOISearch in Google Scholar
[3. TANASESCU C, BĂLĂNESCU E, BĂLĂNESCU P, OLTEANU R, BADEA C, GRANCEA C, et al. IL-17 in cutaneous lupus erythematosus. Eur J Intern Med. 2010; 21 (3):202-7.10.1016/j.ejim.2010.03.004]Open DOISearch in Google Scholar
[4. BLAUVELT A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol. 2008; 128 (5):1064-7.10.1038/jid.2008.85]Search in Google Scholar
[5. CHEN DY, CHEN YM, LAN JL, LIN CC, CHEN HH, HSIEH CW. Potential role of Th17cells in the pathogenesis of adult-onset Still’s disease. Rheumatology (Oxford). 2010; 49 (12):2305-12.10.1093/rheumatology/keq284]Search in Google Scholar
[6. DE NITTO D, SARRA M, CUPI ML, PALLONE F, MONTELEONE G. Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases. Curr Pharm Des. 2010; 16 (33):3656-60.10.2174/138161210794079164]Search in Google Scholar
[7. ZHANG L, LI YG, LI YH, QI L, LIU XG, YUAN CZ, et al. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One. 2012; 7 (4):e31000.10.1371/journal.pone.0031000]Search in Google Scholar
[8. RAYCHAUDHURI SP, RAYCHAUDHURI SK. IL-23/IL-17 axis in spondyloarthritis-bench to bedside. Clin Rheumatol. 2016; 35 (6):1437-41.10.1007/s10067-016-3263-4]Search in Google Scholar
[9. LUBRANO E, PERROTTA FM. Secukinumab for ankylosing spondylitis and psoriatic arthritis. Ther Clin Risk Manag. 2016; 12:1587-92.10.2147/TCRM.S100091]Search in Google Scholar
[10. KURASAWA K, HIROSE K, SANO H, ENDO H, SHINKAI H, NAWATA Y, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum. 2000; 43 (11):2455-63.10.1002/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K]Search in Google Scholar
[11. MURATA M, FUJIMOTO M, MATSUSHITA T, HAMAGUCHI Y, HASEGAWA M, TAKEHARA K, et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci. 2008; 50(3):240-2.10.1016/j.jdermsci.2008.01.00118329249]Open DOISearch in Google Scholar
[12. GOURH P, ARNETT FC, ASSASSI S, TAN FK, HUANG M, DIEKMAN L, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther, 2009; 11 (5):R147.10.1186/ar2821278725919799786]Open DOISearch in Google Scholar
[13. HIGGS BW, ZHU W, RICHMAN L, FIORENTINO DF, GREENBERG SA, JALLAL B, et al. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients. Int J Rheum Dis. 2012; 15 (1):25-35.10.1111/j.1756-185X.2011.01654.x22324944]Open DOISearch in Google Scholar
[14. TOROK KS, KURZINSKI K, KELSEY C, YABES J, MAGEE K, VALLEJO AN, et al. Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. Semin Arthritis Rheum. 2015; 45 (3):284-93.10.1016/j.semarthrit.2015.06.006465612526254121]Search in Google Scholar
[15. OLEWICZ-GAWLIK A, DANCZAK-PAZDROWSKA A, KUZNAR-KAMINSKA B, GORNOWICZ-POROWSKA J, KATULSKA K, TRZYBULSKA D, et al. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis. Int J Rheum Dis. 2014; 17 (6):664-70.10.1111/1756-185X.1229024467649]Open DOISearch in Google Scholar
[16. BĂLĂNESCU P, LĂDARU A, BĂLĂNESCU E, NICOLAU A, BĂICUŞ C, DAN GA. IL-17, IL-6 and IFN-γ in Systemic Sclerosis Patients. Rom J Intern Med. 2015; 53 (1):44-9.10.1515/rjim-2015-000626076560]Search in Google Scholar
[17. OKAMOTO Y, HASEGAWA M, MATSUSHITA T, HAMAGUCHI Y, HUU DL, IWAKURA Y, et al. Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum. 2012; 64 (11):3726-35.10.1002/art.3464322833167]Open DOISearch in Google Scholar
[18. LEI L, HE ZY, ZHAO C, SUN XJ, ZHONG XN. Elevated frequencies of CD4(+) IL-21(+) T, CD4(+) IL-21R(+) T and IL-21 (+) Th17 cells, and increased levels of IL-21 in bleomycin-induced mice may be associated with dermal and pulmonary inflammation and fibrosis. Int J Rheum Dis. 2016; 19 (4):392-404.10.1111/1756-185X.1252225545680]Search in Google Scholar
[19. LEI L, ZHONG XN, HE ZY, ZHAO C, SUN XJ. IL-21 induction of CD4+ T cell differentiation into Th17 cells contributes to bleomycin-induced fibrosis in mice. Cell Biol Int. 2015; 39 (4):388-99.10.1002/cbin.1041025492803]Search in Google Scholar
[20. RADSTAKE TR, VAN BON L, BROEN J, HUSSIANI A, HESSELSTRAND R, WUTTGE DM, et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenoltypes. PLoS One. 2009; 4 (6):e5903.10.1371/journal.pone.0005903269199119536281]Search in Google Scholar
[21. FENOGLIO D, BATTAGLIA F, PARODI A, STRINGARA S, NEGRINI S, PANICO N, RIZZI M, et al. Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol. 2011; 139 (3):249-57.10.1016/j.clim.2011.01.01321419712]Search in Google Scholar
[22. PAPP G, HORVATH IF, BARATH S, GYIMESI E, SIPKA S, SZODORAY P, et al. Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol. 2011; 40 (3):205-10.10.3109/03009742.2010.52802121366383]Search in Google Scholar
[23. TRUCHETET ME, BREMBILLA NC, MONTANARI E, ALLANORE Y, CHIZZOLINI C. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther. 2011; 13(5):R166.10.1186/ar3486330810021996293]Open DOISearch in Google Scholar
[24. ALMANZAR G, KLEIN M, SCHMALZING M, HILLIGARDT D, EL HAJJ N, KNEITZ H, et al. Disease manifestation and inflammatory activity as modulators of Th17/Treg balance and RORC/FoxP3 Methylation in Systemic Sclerosis. Int Arch Allergy Immunol. 2016; 171(2):141-54.10.1159/00045094927902985]Search in Google Scholar
[25. RODRÍGUEZ-REYNA TS, FURUZAWA-CARBALLEDA J, CABIEDES J, FAJARDO-HERMOSILLO LD, MARTÍNEZ-REYES C, DÍAZ-ZAMUDIO M, et al. Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int. 2012; 32 (9):2653-60.10.1007/s00296-011-2056-y21789610]Open DOISearch in Google Scholar
[26. LIU X, GAO N, LI M, XU D, HOU Y, WANG Q, et al. Elevated levels of CD4(+)CD25(+)FoxP3(+) T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction. PLoS One. 2013; 8 (6):e64531.10.1371/journal.pone.0064531367912823776439]Search in Google Scholar
[27. FURUZAWA-CARBALLEDA J, ORTÍZ-ÁVALOS M, LIMA G, JURADO-SANTA CRUZ F, LLORENTE L. Subcutaneous administration of polymerized type I collagen downregulates interleukin (IL)-17A, IL-22 and transforming growth factor-β1 expression, and increases FoxP3-expressing cells in localized scleroderma. Clin Exp Dermatol. 2012; 37 (6):599-609.10.1111/j.1365-2230.2012.04385.x22731679]Search in Google Scholar
[28. NAKASHIMA T, JINNIN M, YAMANE K, HONDA N, KAJIHARA I, MAKINO T, MASUGUCHI S, et al. Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol. 2012; 188 (8):3573-83.10.4049/jimmunol.110059122403442]Search in Google Scholar
[29. LONATI PA, BREMBILLA NC, MONTANARI E, FONTAO L, GABRIELLI A, VETTORI S, et al. High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis. PLoS One. 2014; 9 (8):e105008.10.1371/journal.pone.0105008413815225136988]Search in Google Scholar
[30. BREMBILLA NC, MONTANARI E, TRUCHETET ME, RASCHI E, MERONI P, CHIZZOLINI C. Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res Ther. 2013; 15 (5):R151.10.1186/ar4334397912324289089]Open DOISearch in Google Scholar
[31. FRECH TM, REVELO MP, DRAKOS SG, MURTAUGH MA, MARKEWITZ BA, SAWITZKE AD, LI DY. Vascular leak is a central feature in the pathogenesis of systemic sclerosis. J Rheumatol 2012; 39:1385-91.10.3899/jrheum.111380364027222660809]Search in Google Scholar
[32. LIU M, YANG J, XING X, CUI X, LI M. Interleukin-17A promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway. Arthritis Res Ther. 2014; 16 (6):4223.10.1186/s13075-014-0512-2431676525551434]Open DOISearch in Google Scholar
[33. XING X, YANG J, YANG X, WEI Y, ZHU L, GAO D, et al. IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway. PLoS One. 2013; 8 (12):e85032.10.1371/journal.pone.0085032387163324376862]Search in Google Scholar
[34. YANG X, YANG J, XING X, WAN L, LI M. Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther. 2014; 16 (1):R4.10.1186/ar4430397914224398084]Search in Google Scholar
[35. ZHOU Y, HOU W, XU K, HAN D, JIANG C, MOU K, et al. The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis. Hum Immunol. 2015; 76 (1):22-9.10.1016/j.humimm.2014.12.00825500255]Search in Google Scholar
[36. MELONI F, SOLARI N, CAVAGNA L, MOROSINI M, MONTECUCCO CM, FIETTA AM. Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis. Clin Exp Rheumatol. 2009; 27 (5):765-72.]Search in Google Scholar
[37. ROLLA G, FUSARO E, NICOLA S, BUCCA C, PERONI C, PARISI S, et al. Th-17 cytokines and interstitial lung involvement in systemic sclerosis. J Breath Res. 2016; 10 (4):046013.10.1088/1752-7155/10/4/04601327869103]Search in Google Scholar
[38. HSU E, SHI H, JORDAN RM, LYONS-WEILER J, PILEWSKI JM, FEGHALI-BOSTWICK CA. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 2011; 63 (3):783-94.10.1002/art.30159313981821360508]Open DOISearch in Google Scholar
[39. FAVA A, CIMBRO R, WIGLEY FM, LIU QR, ROSEN A, BOIN F. Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma. Arthritis Res Ther. 2016; 18 (1):9.10.1186/s13075-016-0993-2485729327145754]Open DOISearch in Google Scholar